Clinical Course of Bio Naive Ulcerative Colitis Patients Five Years After Initiation of Adalimumab in a Nationwide Cohort.

Ramaswamy Sundararajan Manthankumar Patel Janak Bahirwani Chinmay Trivedi Nadim Mahmud Nabeel Khan

Published in: Crohn's & colitis 360 (2024)

Among bio-naive UC patients who were started on ADA, a third were still on the drug at the end of 5 years and half had endoscopic remission. The rate of discontinuation was highest within the first year of initiation, but patients continued to stop the drug over the course of follow-up.

Keyphrases

end stage renal disease
ulcerative colitis
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
emergency department
cross sectional
drug induced
patient reported